Topics

Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/PgCxM0mm3K

14:00 EDT 13 Sep 2019 | Pharmafile

Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ 

Original Article: Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/PgCxM0mm3K

NEXT ARTICLE

More From BioPortfolio on "Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/PgCxM0mm3K"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...